Tanezumab offers an exciting new class of analgesics targetting nerve growth factor that has the potential to change the treatment of pain particularly low backache and osteoarthritis. Acute and chronic pain states remain challenging to treat, yet there are several classes of drugs as NSAIDs, opioids, and neuropathic agents, but they may result in poorly tolerated side effects. Anti-NGF antibodies are a novel therapy in pain management and have shown promise in the treatment of conditions that are currently poorly treated.
To use anti-NGF antibodies for different pain conditions, it has shown to have some benefit on chronic low back pain and osteoarthritis pain relief and functional improvement, but additional data are necessary to determine efficacy and safety. Further investigations are required as the data are lacking for the utility of the drug in postherpetic neuralgia. Other…
